Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : John Pitera's Market Laboratory -- Ignore unavailable to you. Want to Upgrade?

To: John Pitera who wrote (3901)	5/23/2001 1:07:52 PM
From: John Pitera	Respond to of 33421

The price target put on GENE and the way it was arrived at today are scary ....reminiscent of last spring..... 09:55 ET Genome Thera (GENE) 10.41 +0.91 (+9.5%): Ladenburg Thalmann morning drawing buyers to the stock; GENE was one of four genomics stocks initiated this morning by the firm with Strong Buy ratings; causing stock to stand out from the rest of group is firm's extremely aggressive price target... Ladenburg Thalmann sees stock reaching $84 over the next 12 months; expects company's expertise in using pathogen genomes to lead to the discovery of several anti-infective agents; firm arrives at valuation using a multiple to R&D expenditures, which averages 54x for drug companies and 65x for large cap biotechs.